TRIP13在非小细胞肺腺癌中促增殖侵袭和血管生成的影响及作用机制

doi:10.3969/j.issn.1006-6233.2022.04.02

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1957 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effects of thyroid hormone receptor interactor 13 (TRIP13) on proliferation, invasion and angiogenesis in non-small-cell lung cancer (NSCLC) and its related mechanisms. Methods: Forty-five NSCLC patients' tumours and their corresponding paraneoplastic tissues were collected. The expression of TRIP13 in the tumours and paraneoplastic tissues was measured by qRT-PCR and analysed for correlation with the patients' clinical characteristics. The expression of TRIP13 in human lung adenocarcinoma cell line A549 and lung squamous carcinoma cell line SKMES1 was measured. PLK-TRIP13 was transfected into A549 and SKMES1 by lentiviral transfection, and its relationship with NSCLC cell proliferation, invasion and angiogenesis was analysed.Results: TRIP13 was highly expressed in tumor tissues compared with adjacent tissues. TRIP13 high expression correlated with tumor type, tumor stage, and lymph node metastasis. TRIP13 high expression significantly promoted proliferation, invasion and angiogenesis of A549 cells, but not of SKMES1 cells.Conclusion: TRIP13 can promote proliferation, invasion and angiogenesis of non-small cell lung adenocarcinoma, and detection of TRIP13 and NSCLC pathological types can serve as a potential clinical treatment option for lung adenocarcinoma.

Key words： Non-small cell lung cancer Adenocarcinoma Thyroid hormone receptor interactor 13 Proliferation and invasion Angiogenesis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.04.02 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I4/534

[1] Ferlay J,Colombet M,Soerjomataram I,et al.Cancer statistics for the year 2020:an overview [J].Int Cancer,2021,10(1):1002.
[2] Friedlaender A,Addeo A,Russo A,et al.Targeted therapies in early stage NSCLC:hype or hope [J].Int Mol Sci,2020,21(17):6329.
[3] 李晓华,李洁,唐军伟.外周血循环肿瘤细胞和肿瘤标志物在评估老年非小细胞肺癌患者化疗后疗效中的价值[J].河北医学,2021,27(5):779~785.
[4] Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer [J].Nature,2018,553(7689):446~454.
[5] Lu S,Qian J,Guo M,et al.Insights into a crucial role of TRIP13 in human cancer [J].Comput Struct Biotechnol,2019,17(1):854~861.
[6] Agarwal S,Behring M,Kim HG,et al.TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status [J].Mol Oncol,2020,14(12):3007~3029.
[7] Zhou XY,Shu XM.TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway [J].Eur Rev Med Pharmacol Sci,2019,23(2):522~529.
[8] Zhang Q,Dong Y,Hao S,et al.The oncogenic role of TRIP13 in regulating proliferation,invasion,and cell cycle checkpoint in NSCLC cells [J].Int Clin Exp Pathol,2019,12(9):3357~3366.
[9] Yu L,Xiao Y,Zhou X,et al.TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression [J].Biomed Pharmacother,2019,120(1):109508.
[10] Agarwal S,Behring M,Kim HG,et al.TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status [J].Mol Oncol,2020,14(12):3007~3029.
[11] Li W,Zhang G,Li X,et al.Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma [J].Biochem Biophys Res Commun,2018,499(3):416~424.
[12] Apte RS,Chen DS,Ferrara N.VEGF in signaling and disease:beyond discovery and development [J].Cell,2019,176(6):1248~1264.